| Envoy Of Westover Hills | |
| 4403 Forest Hill Avenue, Richmond, Virginia 23225 | |
| (804) 231-0231 | |
| Name | Envoy Of Westover Hills |
|---|---|
| Location | 4403 Forest Hill Avenue, Richmond, Virginia |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 174 |
| Occupancy Rate | 62.18% |
| Medicare ID (CCN) | 495327 |
| Legal Business Name | Envoy Of Richmond, Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1598480071 |
| Organization Name | WESTOVER HILLS SNF OPERATIONS LLC |
| Address | 4403 Forest Hill Ave, Richmond, VA 23225 |
| Phone Number | 804-231-0231 |
News Archive
Active Biotech and Ipsen today announced that the Phase III clinical trial for tasquinimod, a novel compound for the treatment of prostate cancer, is successfully enrolled with over 1,200 randomized patients as planned in the clinical protocol.
Eurofins Biomnis has considerably improved sample preparation productivity in its specialized clinical pathology laboratory.
Most Australian GPs have used a placebo in practice at least once, with active placebos (active treatments used primarily to generate positive expectations) more commonly used than inert placebos, according to a new study.
The American Botanical Council has presented its 2013 Varro E. Tyler Commercial Investment in Phytomedicinal Research Award to Wakunaga Pharmaceutical Company, Ltd., of Osaka, Japan. Since its founding in 1955, the company has been committed to rigorous scientific and clinical research of its products, including its top-selling, clinically researched odorless Aged Garlic Extract¨.
› Verified 2 days ago
| NPI Number | 1861416349 |
| Organization Name | FOREST HILL CONVALESCENT CENTER, LP |
| Doing Business As | RUXTON HEALTH AND REHABILITATION CENTER OF WESTOVER HILLS |
| Address | 4403 Forest Hill Ave, Richmond, VA 23225 |
| Phone Number | 804-231-0231 |
News Archive
Active Biotech and Ipsen today announced that the Phase III clinical trial for tasquinimod, a novel compound for the treatment of prostate cancer, is successfully enrolled with over 1,200 randomized patients as planned in the clinical protocol.
Eurofins Biomnis has considerably improved sample preparation productivity in its specialized clinical pathology laboratory.
Most Australian GPs have used a placebo in practice at least once, with active placebos (active treatments used primarily to generate positive expectations) more commonly used than inert placebos, according to a new study.
The American Botanical Council has presented its 2013 Varro E. Tyler Commercial Investment in Phytomedicinal Research Award to Wakunaga Pharmaceutical Company, Ltd., of Osaka, Japan. Since its founding in 1955, the company has been committed to rigorous scientific and clinical research of its products, including its top-selling, clinically researched odorless Aged Garlic Extract¨.
› Verified 2 days ago
| NPI Number | 1982857025 |
| Organization Name | ENVOY OF RICHMOND, LLC |
| Doing Business As | ENVOY OF WESTOVER HILLS |
| Address | 4403 Forest Hill Ave, Richmond, VA 23225 |
| Phone Number | 804-231-0231 |
News Archive
Active Biotech and Ipsen today announced that the Phase III clinical trial for tasquinimod, a novel compound for the treatment of prostate cancer, is successfully enrolled with over 1,200 randomized patients as planned in the clinical protocol.
Eurofins Biomnis has considerably improved sample preparation productivity in its specialized clinical pathology laboratory.
Most Australian GPs have used a placebo in practice at least once, with active placebos (active treatments used primarily to generate positive expectations) more commonly used than inert placebos, according to a new study.
The American Botanical Council has presented its 2013 Varro E. Tyler Commercial Investment in Phytomedicinal Research Award to Wakunaga Pharmaceutical Company, Ltd., of Osaka, Japan. Since its founding in 1955, the company has been committed to rigorous scientific and clinical research of its products, including its top-selling, clinically researched odorless Aged Garlic Extract¨.
› Verified 2 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Active Biotech and Ipsen today announced that the Phase III clinical trial for tasquinimod, a novel compound for the treatment of prostate cancer, is successfully enrolled with over 1,200 randomized patients as planned in the clinical protocol.
Eurofins Biomnis has considerably improved sample preparation productivity in its specialized clinical pathology laboratory.
Most Australian GPs have used a placebo in practice at least once, with active placebos (active treatments used primarily to generate positive expectations) more commonly used than inert placebos, according to a new study.
The American Botanical Council has presented its 2013 Varro E. Tyler Commercial Investment in Phytomedicinal Research Award to Wakunaga Pharmaceutical Company, Ltd., of Osaka, Japan. Since its founding in 1955, the company has been committed to rigorous scientific and clinical research of its products, including its top-selling, clinically researched odorless Aged Garlic Extract¨.
› Verified 2 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 5 |
| Total Amount of Fines in Dollars | $507016 |
| Number of Payment Denials | 1 |
| Total Number of Penalties | 6 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 29.25 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 2.23 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 49.22 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 3.02 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0.43 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 1.85 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 99.59 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 12.1 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 88.41 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 39.17 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 16.35 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 3.81 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 99.62 | 95.98 |